Deciphering the YY1/ lncRNA BLACAT1/miR-605-3p axis in glioblastoma: implications for therapy

Deciphering the YY1/ lncRNA BLACAT1/miR-605-3p axis in glioblastoma: implications for therapy

Abstract Glioblastoma multiforme (GBM), an aggressive brain cancer, requires novel therapeutic targets. This study investigates the YY1/lncRNA BLACAT1/miR-605-3p regulatory network in GBM pathogenesis. Using bioinformatics tools and TCGA-GBM datasets, we identified six miR-605-3p target genes (ARPC1...

Full description

Saved in:
Bibliographic Details
Main Authors: Liang Han, Han Wang, Hong Xie, Xiuming Yu, Haixia Zhou, Zhigang Guo
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-01001-9
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Glioblastoma multiforme (GBM), an aggressive brain cancer, requires novel therapeutic targets. This study investigates the YY1/lncRNA BLACAT1/miR-605-3p regulatory network in GBM pathogenesis. Using bioinformatics tools and TCGA-GBM datasets, we identified six miR-605-3p target genes (ARPC1B, FOSL1, H6PD, ITGA3, LMAN1, and PXN) strongly correlated with YY1 (p < 0.01). In GBM cells, YY1 mRNA increased ~3.8-fold (p < 0.01), BLACAT1 ~ 2.4–2.7-fold (p < 0.01), and target genes ~1.8–2.5-fold (p < 0.05), while miR-605-3p decreased to ~0.3-fold (p < 0.01). YY1 knockout reduced BLACAT1 to 0.33 (p < 0.001), reversed by miR-605-3p inhibition. YY1 knockout inhibited migration (53–75%, p < 0.001), invasion (53–62%, p < 0.001), colony formation (43–53%, p < 0.001), and angiogenesis (p < 0.01). In U251 xenograft models, YY1 knockout reduced tumor volume from 2036 to 260 mm³ (p < 0.0001), partially restored to 1558 mm³ (p < 0.0001) by miR-605-3p antagomir, while agomir reduced it to 721 mm³ (p < 0.01). YY1 promoted angiogenesis, oxidative stress, inflammation, and fibrosis (p < 0.05), countered by miR-605-3p (p < 0.05). Validations included RT-qPCR, ChIP-qPCR, immunofluorescence, dual-luciferase assays, and immunohistochemistry. The YY1/BLACAT1/miR-605-3p axis drives GBM progression, offering therapeutic potential.
ISSN:2397-768X

Similar Items